Standout Papers

Secukinumab in Plaque Psoriasis — Results of ... 2001 2026 2009 2017 1.4k
  1. Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials (2014)
    Richard G. Langley, Boni E. Elewski et al. New England Journal of Medicine
  2. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) (2008)
    Kim Papp, Richard G. Langley et al. The Lancet
  3. Guidelines of care for the management of psoriasis and psoriatic arthritis (2008)
    Alan Menter, Alice B. Gottlieb et al. Journal of the American Academy of Dermatology
  4. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. (2001)
    Gerald G. Krueger, John Koo et al. PubMed
  5. Psoriasis (2016)
    Jacqueline Greb, Ari M. Goldminz et al. Nature Reviews Disease Primers
  6. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials (2015)
    C.E.M. Griffiths, Kristian Reich et al. The Lancet
  7. Guidelines of care for the management of psoriasis and psoriatic arthritis (2008)
    Alice B. Gottlieb, Neil J. Korman et al. Journal of the American Academy of Dermatology
  8. A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis (2007)
    Gerald G. Krueger, Richard G. Langley et al. New England Journal of Medicine
  9. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials (2018)
    Kenneth B. Gordon, Bruce Strober et al. The Lancet
  10. Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey (2014)
    Mark Lebwohl, H. Bachelez et al. Journal of the American Academy of Dermatology
  11. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults (2016)
    Amy S. Paller, Wynnis L. Tom et al. Journal of the American Academy of Dermatology
  12. Psoriasis: Which therapy for which patient (2018)
    Shivani B. Kaushik, Mark Lebwohl Journal of the American Academy of Dermatology
  13. Bimekizumab versus Secukinumab in Plaque Psoriasis (2021)
    Kristian Reich, Richard B. Warren et al. New England Journal of Medicine
  14. Trial of Spesolimab for Generalized Pustular Psoriasis (2021)
    H. Bachelez, Siew Eng Choon et al. New England Journal of Medicine
  15. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial (2021)
    Kristian Reich, Kim Papp et al. The Lancet
  16. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo (2022)
    David Rosmarin, Thierry Passeron et al. New England Journal of Medicine
  17. Remibrutinib in Chronic Spontaneous Urticaria (2025)
    Martin Metz, Michihiro Hide et al. New England Journal of Medicine

Immediate Impact

11 by Nobel laureates 18 from Science/Nature 124 standout
Sub-graph 1 of 15

Citing Papers

Active biointegrated living electronics for managing inflammation
2024 StandoutScience
Psoriasis
2021 Standout
1 intermediate paper

Works of Mark Lebwohl being referenced

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
2018 Standout
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
2008 Standout
and 6 more

Author Peers

Author Last Decade Papers Cites
Mark Lebwohl 22034 17465 3922 5458 807 34.6k
Kim Papp 23568 15724 2118 6964 528 31.4k
Kristian Reich 19466 13460 2150 4889 491 25.3k
Alice B. Gottlieb 22317 11858 2213 8621 573 30.3k
Alan Menter 18409 11772 1828 4555 375 24.5k
James G. Krueger 29895 24382 2801 5571 487 48.2k
Giampiero Girolomoni 12086 9588 2265 3699 539 23.0k
Juliet N. Barker 16763 8700 2806 2705 539 30.3k
Joel M. Gelfand 13768 8901 2057 4978 277 20.9k
L. Puig 10766 7372 2398 3649 617 17.5k
Thomas Ruzicka 6096 11488 3735 3180 660 25.3k

All Works

Loading papers...

Rankless by CCL
2026